Načítá se...
Insulin degludec aspart: One-year real world experience
BACKGROUND: This retrospective analysis describes the use of insulin degludec aspart (IDegAsp) in India. MATERIAL AND METHODS: All subjects who had received IDegAsp for 52 weeks at two endocrine centers were included in this study. RESULTS: Forty-eight subjects (40 men), with mean age of 54.33 ± 9.6...
Uloženo v:
| Vydáno v: | Indian J Endocrinol Metab |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Medknow Publications & Media Pvt Ltd
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4855967/ https://ncbi.nlm.nih.gov/pubmed/27186556 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.177416 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|